Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNV-166
- Development stage
- Phase 1
- Lead developer
- Invitro Research Solutions
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
RNV-166 is an orally administered small molecule drug candidate being developed by InVitro Research Solutions for the treatment of type 2 diabetes mellitus. It has been evaluated in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial in healthy male volunteers to assess its safety, tolerability, and pharmacokinetics. Additionally, a Phase 2a clinical trial has been approved to evaluate the safety, tolerability, and pharmacodynamics of RNV-166 capsules in male participants with early type 2 diabetes mellitus.
Beyond the preview
Go deeper on RNV-166.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNV-166.